Does a long preclinical period occur in Parkinson’s disease?

Neurology

Volumn 41, Issue , 1991, Pages 8-13

  Koller, W C ^a   Langston, J W ^b   Hubble, J P ^a   Irwin, I ^b   Zack, M ^c   Golbe, L ^d   Forno, L ^e   Ellenberg, J ⁱ   Kurland, L ^j   Ruttenber, A J ^c   Spencer, P ^k   Tanner, C ^b   Tetrud, J ^b   Wilcox, T ^l   Roman, G ^g   Mayeux, R ^f   Smith, M ^h   Goetz, C ^m  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b California Parkinson s Foundation   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^f Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NINDS ^*  (United States)

^j MAYO CLINIC   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^m RUSH UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; NERVOUS SYSTEM; NEUROLOGIC DISEASE; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; REACTION TIME; REVIEW; SCINTISCANNING;

BRAIN; HUMAN; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES; PARKINSON DISEASE; REACTION TIME; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0026164384     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.41.5_Suppl_2.8     Document Type: Article

References (108)

1. Duvoisin RC. On the causes of Parkinson’s disease. In: Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworth Scientific, 1982.
2. Langston JW. Etiology of Parkinson’s disease. In: Koller WC, ed. Handbook of Parkinson’s disease. New York: Marcel Dekker, 1986:297-309.
3. Caine DB. Current concepts on the etiology of Parkinson’s disease. Movement Disorders 1989;4 (supp 1):511-514.
4. Caine DB, Langston JW. Aetiology of Parkinson’s disease. Lancet 1983;ii:1457-1459.
5. Langston JW. Mechanisms underlying neuronal degeneration in Parkinson’s disease: An experimental and theoretical treatise. Movement Disorder 1989;4(suppl 1):515-525.
6. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 1989; 245:519-522.
7. Parkinson Study Group. DAT ATOP: a multi-center controlled clinical trial in early Parkinson’s disease. Arch Neurol 1989;46:1502-1060.
8. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989;321:1364-1371.
9. Shoulson I: Preventive therapies for Parkinson’s disease. In: Koller WC and Paulson G, eds. Therapy for Parkinson’s disese. New York: Marcel-Dekker Inc. 1990:3S7-368.
10. Caine DB, McGeer E, Eisen A, Spencer P. Alzheimer’s disease, Parkinson’s disease, and motoneurone disease: Abiotrophic interaction between aging and environment? Lancet 1986; ii:1067-1070.
11. Gowers WR. A lecture on abiotrophy. Lancet 1902;i:1003-1007.
12. McGeer PL, McGeer ED, Suzuki JS. Aging and extrapyramidal function. Arch Neurol 1977;34:33-35.
13. Tomlinson BE, Irving D. The numbers of limb motor neurons in the human lumbosacral cord throughout life. J Neurol Sci 1977;34:213.
14. Konigsmark BW, Murphy EA. Neuronal populations in the human brain. Nature 1970;228:1335-1336.
15. Terry RD, DeTeresa R, Hansen LA. Neocortical cell counts in normal human adult aging. Ann Neurol 1987;21:530-539.
16. Spencer, PS. Guam-Parkinsonism dementia caused by slow toxin(s) in food? Can J Neurol Sci 1989;141:347-357.
17. Garruto RM, Yanagihara R, Gajdusek DC. Disappearance of high-incidence amyotrophic lateral sclerosis and parkinsonism- dementia of Guam. Neurology 1985;35:193-198.
18. Snow BJ, Peppard RF, Guttman M, et al. Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amyotrophic lateral sclerosis parkin - sonism dementia complex of Guam. Arch Neurol 1990;47:870-874.
19. Garruto RM, Gajdusek DC, Chen KM. Amyotrophic lateral sclerosis among Charmorro migrants from Guam. Ann Neurol 1980;8:612-619.
20. Abel EN, Hassanein M. Neuropsychiatric manifestations of chronic manganese poisoning. J Neurol Neurosurg Psychiatry 1965;28:282-285.
21. Mena I, Marin O, Fuenzalida S, Cotzias GC. Chronic manganese poisoning. Clinical picture and manganese turnover. Neurology 1967;17:128-136.
22. Ringel SP, Klawans HL. Carbon monoxide-induced parkinsonism. J Neurol Sci 1972; 16:245-251.
23. von Economo C. Encephalitis lethargica. Wien Klin Wochenschr 1917;30:581-585.
24. von Economo C. Die Encephalitis lethargica, ihre Nachkrank- heiten und ihre Behandlung. Berlin: Urban & Schwarzenberg, 1929.
25. Finley KH. Postencephalitis manifestations of viral encepha- litides. In: Fields WS, Blattner RJ, eds. Viral Encephalitis: A Symposium: Sixth annual scientific meeting of Houston Neurological Society. Springfield, Illinois: Thomas, 1958:69-94.
26. Walters JH. Postencephalitic parkinson syndrome after meningoencephalitis due to Coxsackie virus Group B, Type 2. New Engl J Med 1960;263:744-747.
27. Dalakas MC, Elder GI, Hallett M, et al. A long-term follow-up study of patients with post-poliomyelitis. New Engl J Med 1986;314:959-963.
28. Cashman NR, Maselli R, Wollmann RL, Roos R, Simon R, Antel JP. Late denervation in patients with antecedent paralytic poliomyelitis. New Engl J Med 1987;317:7-12.
29. Huntington G. On chorea. Med Surg Reporter Philadelphia 1872;26:317-321.
30. Wilson SAK. Progressive lenticular degeneration; a familial nervous disease associated with cirrhosis of the liver. Brain 1912;34:295-509.
31. Kuhl DH, Metter EJ, Riege WH, Markham CH. Patterns of cerebral glucose utilization in Parkinson’s disease and Huntington’s disease. Ann Neurol 1984;15:5119-5125.
32. Ablin RL, Young AB, Penney J, et al. Abnormalities of striatal projection neurons and N-methyl-D-asparate receptors in pre- symptomatic Huntington’s disease. N Engl J Med 1990; 322:1293-1297.
33. Golbe LI, Dilorio G, Bonavita V, Miller BC, Duvoisin RC. A large kindred with autosomal dominant Parkinson’s disease. Ann Neurol 1990;27:276-282.
34. Klawans HL. Hemiparkinsonism as a late complication of hemiatrophy: A new syndrome. Neurology 1981;31:625-628.
35. Buchman AS, Goetz CC, Klawans HL. Hemiparkinsonism with hemiatrophy. Neurology 1988;38:527-530.
36. Mawdsley CL, Ferguson FR. Neurological disease in boxers. Lancet 1963;ii:795-801.
37. Guterman A, Smith RW. Neurological sequelae of boxing. Sports Med 1987;4:194-210.
38. Jankovic J. Pathophysiology and clinical assessment of motor symptoms in Parkinson’s disease. In: Koller WC, Paulson GW, eds. Therapy for Parkinson’s disease. New York: Marcel-Dekker, 1990:99-126.
39. Stern Y, Tetrud JW, Martin WRW, Kutner ST, Langston JW. Cognitive changes following MPTP exposure. Neurology 1990;40:261-264.
40. Koller WC, Wong GF, Lang A. Post-traumatic movement disorders. A review. Movement Disorders 1989;4:20-36.
41. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054-1060.
42. Korczyn AD, Goldberg GJ. Extrapyramidal effects of neuroleptics. J Neurol Neurosurg Psychiatry 1976;39:866-869.
43. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988:850-854.
44. Goetz CG. Drug-induced parkinsonism and idiopathic Parkinson’s disease. Arch Neurol 1983;40:325-326.
45. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984;ii:1082-1083.
46. Rajput AH, Rozdilsky B, Kornykiewicz O, Shannak K, Lee T, Seeman P. Reversible drug-induced parkinsonism: clinicopatho- logic study of two cases. Arch Neurol 1982;39:644-646.
47. Jelliffe SE. The Parkinsonian body posture; some considerations on unconscious hostility. Psychoanal Rev 1940;27:467-479.
48. Sands I. The type of personality susceptible to Parkinson’s disease. Mt Sinai J Med 1943;9:192-194.
49. Booth G. Psychodynamics in Parkinsonism. Psychosom Med 1948;10:1-14.
50. Prichard JS, Schwab RS, Tillman WA. The effects of stress and results of medication in different personalities with Parkinson’s disease. Psychosom Med 1951;13:106-111.
51. Diller L, Riklan M. Psychosocial factors in Parkinson’s disease. J Am Geriatr Soc 1956;4:1291-1300.
52. Machover S. Rorschach study on the nature and origin of common factors in the personalities of Parkinsonians. Psychosom Med 1957;19:332-338.
53. Ogawa T. Personality characteristics of Parkinson’s disease. Percept Mot Skills 1981;52:375-378.
54. Poewe W, Gerstenbrand F, Ransmayr G, Plorer S. Pre-morbid personality of Parkinson patients. J Neural Transm Suppl 1983; 19:215-224.
55. Baumann RJ, Jameson HD, McKean HE, Haack DG, Weisberg LM. Cigarette smoking in Parkinson’s disease: 1. A comparison of cases with matched neighbors. Neurology 1980;30:839-843.
56. Martilla RJ, Rinne UK. Smoking and Parkinson’s disease. Acta Neurol Scand 1980;62:322-325.
57. Golbe LI, Cody RA, Duvoisin RC. Smoking and Parkinson’s disease. Search of a dose-response relationship. Arch Neurol 1986;43:774-778.
58. Pollock M, Homabrook RW. The prevalence, natural history and dementia of Parkinson’s disease. Brain 1966;89:429-488.
59. Duvoisin RC, Eldridge R, Williams A, Nutt J, Caine D. Twin study of Parkinson disease. Neurology 1981;31:77-80.
60. Mayeux R, Stern Y, Rosen J, Leventhal J. Depression, intellectual impairment, and Parkinson’s disease. Neurology 1981; 31:645-50.
61. Santamaria J, Tolosa E, Valles A. Parkinson’s disease with depression: A possible subgroup of idiopathic parkinsonxism. Neurology 1986;36:1130-1133.
62. Mindham RHS. Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 1970;33:188-191.
63. Robins AH. Depression in patients with parkinsonism. Br J Psychiatry 1976;128:141-145.
64. Brown GL, Wilson WP. Parkinsonism and depression. South Med J 1972;65:540-545.
65. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
66. Stern Y, Langston JW. Intellectual changes in patients with MPTP- induced parkinsonism. Neurology 1980;35:1506-1509.
67. Tanner CM, Goetz CG, Klawans HL. Autonomic nervous system disorders. In: Roller WC, ed. Handbook of Parkinson’s disease. New York: Marcel-Dekker 1987:145-170.
68. Fomo LS, Norville RC. Ultrastructure of Lewy bodies in the stellate ganglion. Acta Neuropathol (Berlin) 1976;34:183-197.
69. Qualman SJ, Haupt HM, Yang P, et al. Esophageal Lewy bodies associated with ganglion cell loss in achalasia: similarity to Parkinson’s disease. Gastroenterology 1984;87:848-856.
70. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses. Acta Neuropathologica 1988; 76:217-221.
71. Stadlan EM, Duvoisin RC, Yahr M. The pathology of parkinsonism. In: Luthy F, Bischoff A, eds. Proceedings of the 5th International Congress of Neuropathology. Amsterdam: Excerpta Medica, 1966:569-571.
72. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: A general deficit unrelated to neurologic signs, disease, stage, or disease duration. Neurology 1988;38:1237-1244.
73. Doty RL, Riklan M, Dema DA, Reynolds C, Stellar S. The olfactory and cognitive deficits of Parkinson’s disease: Evidence for independence. Ann Neurol 1989;25:166-171.
74. Snider SR, Sandyk N. Sensory dysfunction. In: Roller WC, ed. Handbook of Parkinson’s disease. New York: Marcel-Dekker, 1987:171-180.
75. Snider SR, Fahn S, Isgacen WD, Cote LJ. Primary sensory symptoms in parkinsonism. Neurology 1976;26:423-429.
76. Roller WC. Sensory symptoms in Parkinson’s disease. Neurology 1984;34:957-959.
77. Tanner CM. The role of environmental toxins in the etiology of Parkinson’s disease. Trends in Neuroscience 1989;12:49-54.
78. Nefzger MD, Quadfasel FA, Karl VC. A retrospective study of smoking in Parkinson’s disease. Am J Epidemiol 1968;88:149-158.
79. Kessler II, Diamond EL. Epidemiologic studies of Parkinson’s disease: I. Smoking and Parkinson’s disease: A survey and explanatory hypothesis. Am J Epidemiol 1971;94:16-25.
80. Marttila RJ, Rinne UK. Smoking and Parkinson’s disease. Acta Neurol Scand 1980;62:322-325.
81. Godwin-Austin RB, Lee PN, Marmot MG, Stern GM. Smoking and Parkinson’s disease. J Neurol Neurosurg Psychiatry 1982;45:577-581.
82. Rajput AH, Uitti RJ, Stern W, et al. Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson’s disease. Can J Neurol Sci 1987;14:414-418.
83. Tanner CM, Chen B, Wang WZ, et al. Environmental factors in the etiology of Parkinson’s disease. Can J Neurol Sci 1987;14:419-423.
84. Ho SC, Woo J, Lee CM. Epidemiologic study of Parkinson’s disease in Hong Kong. Neurology 1989;39:1314-1318.
85. Roller W, Vetere-Overfield B, Gray C, et al. Environmental risk factors in Parkinson’s disease. Neurology 1990;40:1218-1223.
86. Golbe LI, Farrell TM, Davis PH. Follow-up study of early life protective and risk factors in PD. Movement Disorders 1990;5:66-70.
87. Tanner CM, Chen B, Wang W, et al. Environmental factors and Parkinson’s disease: A case-control study in China. Neurology 1989;39:660-664.
88. Barbeau A. Cloutier RT, Plasse L, Paris S. Environmental and genetic factors in the etiology of Parkinson’s disease. In: Yahr MD, Bergmann KJ, eds. Advances in Neurology, Vol. 45. New York: Raven Press, 1986:299-306.
89. Greenfield JG, Bosanquet PD. The brainstem lesion in parkinsonism. J Neurol Neurosurg Psychiatry 1953;16:213-226.
90. Fomo LS, Alford EC, Jr. The pathology of parkinsonism. Some observations and new correlations. Contemp Neurol 1971;8:120-130.
91. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973;20:415-455.
92. Hornykiewicz O. Dopamine deficiency and dopamine substitution in Parkinson’s disease. In: Winlow W, Markstein R, eds. The neurobiology of dopamine systems. Manchester: Manchester University Press, 1986:321-328.
93. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson’s disease. J Neural Transm 1976;38:277-301.
94. Hornykiewicz O. Parkinson’s disease and its chemotherapy. Bio-chem Pharmacol 1975;24:1061-1065.
95. Scherman D, Desnos C, Darchen F, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson’s disease: role of aging. Ann Neurol (in press).
96. Agid Y, Cervera P, Hirsch E, et al. Biochemistry of Parkinson’s disease 28 years later. A critical review. Movement Disorders 1989;4:S126-S144.
97. Wooten GF. Neurochemistry, In, Roller WC, ed. Handbook of Parkinson’s disease. New York: Marcel Dekker 1987:237-253.
98. Fomo LS, Alvord EC. Pathology of Parkinson’s disease. In: Roller WC, ed. Handbook of Parkinson’s disease. New York: Marcel-Dekker 1987:209-236.
99. Gibb WRG, Lees AT. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson disease. J Neurol Neurosurg Psychiatry 1988:745-752.
100. Guttman M, Caine DB. In vivo characterization of cerebral dopamine systems in human parkinsonism. In: Jankovic J, Tolosa E, eds. Parkinson’s disease and movement disorders, Baltimore: Urban and Schwarzenberg, 1988:49-58.
101. Caine DB, Langston JW, Martin WRW, et al. Positron emission tomography after MPTP: Observations relating to the cause of Parkinson’s disease. Nature 1985;317:246-248.
102. Duvoisin RC. Genetics of Parkinson’s disease. Adv Neurol 1987; 45:307-312.
103. Johnson WG, Hodge SE, Duvoisin R. Twin studies and the genetics of Parkinson’s disease — a reappraisal. Movement Disorders 1990;5:187-194.
104. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirer J. Ecogenetics of Parkinson’s disease: 4-hydroxylation of debriso- quine. Lancet 1985;ii:1213-1216.
105. Steventon GB, Heafield MTE, Waring RH, Williams AC. Xenobiotic metabolism in Parkinson’s disease. Neurology 1989;39:883-887.
106. Parker WD, Boyson SJ, Parks JK. Electron transport chain abnormalities in idiopathic Parkinson’s disease. Ann Neurol 1989;26:719-723.
107. Schapira AHV, Cooper JM, Dexter D, Jenner P, Clark JN, Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 1990;54:823-827.
108. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological progress. Ann Neurol 1988;24:574-576.